StarInvest’s
Portfolio Company, New Life Scientific Declares Stock Dividend and Announces New
Stock Symbol
New York, February 6, 2006, StarInvest Group,
Inc. (Symbol: STIV:OB), on January 24, 2006 New Life Scientific (NWLS:OB), a Portfolio
company of StarInvest declared a 1.1 to 1 forward stock split of the Company’s
common stock. Each shareholder of record at the close of business on January
25, 2006, will receive 1.1 shares for every share held on the record date. The
split will require any existing shareholder to tender their current shares in
order to receive their forward split shares. The Company also announced a new
trading Symbol:NWLS:OB.
About New Life Scientific, Inc.
New
Life Scientific, Inc. (NLS) develops and commercializes novel biotech and pharmaceutical
products, vaccines and genetic treatment modalities. NLS seeks to expand through
collaborations, acquisitions, in-licensing and research. NLS utilizes its strategic
geographical positioning in Europe to seek undiscovered, emerging and under-valued
biotechnologies in the countries of Eastern Europe, with the further intent of
their commercialization. For additional information see,www.newlifesci.com.
About StarInvest
Group, Inc.
StarInvest
Group is a publicly traded Business Development Company (BDC) located in New York
City. The company has implemented a strategy to create value for shareholders
by investing in emerging companies that are positioned for strong industry growth
or have business models with strong cash flow potential. In addition to structuring
financing requirements, StarInvest provides managerial assistance and strategic
links between the Portfolio Companies enabling them to maximize their resources
for marketing, business development, administration, public listing planning,
and realization of their goals. For more information see www.starinvestgroup.com
.
Safe
Harbor Statements under the Private Securities Litigation Reform Act of 1965:
Those statements contained herein which are not historical are forward-looking
statements, and as such, are subject to risks and uncertainties that could cause
actual operating results to materially differ from those contained in the forward-looking
statements. Such statements include, but are not limited to, certain delays
that are beyond the Company’s control, with respect to market acceptance of new
technologies, or product delays in the testing and evaluation of products, and
other risks, as detailed in the Company’s periodic filings with the Securities
and Exchange Commission.
Contact for StarInvest Group, Inc.,
ir@starinvestgroup.com - (212) 338-0001